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Abstract
Introduction: Screening programs for colorectal cancer (CRC) are mainly based on a first-line fecal immunochemical test for hemoglobin (FIT). Fe-
cal M2-type pyruvate kinase (M2-PK) has been evaluated in clinical settings showing promising results for early CRC detection. However, the impact 
of fecal M2-PK assessment on the performance of first-round CRC screening programs is not known. We investigated whether fecal M2-PK alone or 
in combination with FIT may improve CRC screening efficacy in the general population.
Materials and methods: A total of 1027 asymptomatic subjects (median age 66 [59-74] years; females 504 [49.1%]), identified through the gene-
ral practitioners’ rosters, were invited for the collection of 2 fecal samples for FIT and M2-PK evaluation. Participants with at least positive one fecal 
test were referred for colonoscopy. Quality indicators for screening performance were calculated and analyzed using Fisher’s exact test.
Results: Overall, 572 subjects underwent both FIT and M2-PK assessment (participation rate 55.7%): 93 participants showed positive results for 
at least one test (positivity rate 16.3%). Only 10 patients were positive for both tests. Attendance rate to colonoscopy was 86.0% and a total of 65 
adenomas and 7 cancers were detected. Combined use of FIT and fecal M2-PK permitted the identification of 18 more neoplasm (25%) without im-
proving colonoscopy workload, as deduced by the comparable number needed to scope (P = 0.402).
Conclusion: The addition of M2-PK testing to FIT offers the potential to detect additional neoplasms that either do not bleed or only bleed inter-
mittently without reducing participation rate and without increasing endoscopy workload. 
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Colorectal cancer (CRC) is the third most frequent 
cancer in humans, and is a major health problem 
in developed countries (1). More than 90% of cases 
originate from colorectal adenoma following a 
long, stepwise carcinogenic process (2,3). Thus, 
the early detection and removal of adenomatous 
lesions are crucial in preventing mortality and 
morbidity due to CRC (4). Currently, fecal immuno-
chemical test for hemoglobin (FIT) is considered 
the standard approach for population-screening 
programs whereas total colonoscopy represents 
the gold standard for CRC diagnosis (5). However, 
both FIT and colonoscopy have several limitations 
including low sensitivity and specificity for the for-
mer, and low acceptance rate and expensiveness 
for the latter (6). Consequently, there is fervent in-
terest towards finding new strategies and new ap-
proaches for CRC screening. 
M2-type pyruvate kinase (M2-PK) is an alternative 
form of the enzyme pyruvate kinase that is ex-
pressed during cancer development and plays a 
central role in controlling the metabolism of cells 
with high proliferation rate (7). In CRC and adeno-
ma, M2-PK is released into the feces and can be 
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easily quantified by sandwich enzyme-linked im-
munosorbent assay (ELISA) (8). 
To date, several studies have evaluated fecal M2-
PK levels for CRC detection in high-risk or sympto-
matic populations (6,9). However, only few studies 
have investigated the performance of fecal M2-PK 
in CRC screening programs involving potentially 
healthy subjects (10). Moreover, no data on fecal 
M2-PK efficacy in the first-round screening pro-
grams performed under real practice conditions 
are available. Therefore, in the present study, we 
examined whether fecal M2-PK assessment alone 
or in combination with FIT might improve CRC 
screening efficacy in order to achieve a more accu-




From April 2012 to October 2012, a total of 1027 
asymptomatic average-risk subjects (median age 
66 [59-74] years; females 504 [49.1%]) drawn from 
the general practitioners’ rosters were invited to 
join the present prospective, single-center, popu-
lation-based study in the setting of CRC screening 
program (Centro di Prevenzione Oncologica [CPO 
Piemonte], Molinette Hospital, Turin, Italy). The 
study design is presented in Figure 1. General 
practitioners were asked to exclude from the invi-
tation subjects who had undergone colonoscopy 
within the previous 5 years or with a diagnosis of 
inflammatory bowel disease, taking into account 
Excluded: only FIT or M2-PK returned
n = 201 (19.6%)
66 (61-72) years
Females: 97 (48.3%)
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Figure 1. Flow chart of the study.
Of 1027 invited subjects, 201 were excluded from the study because they provided only fecal immunochemical test for hemoglobin 
(FIT) or M2-type pyruvate kinase (M2-PK) fecal sample, whereas 254 (24.7%) did not respond to the invitation. Overall, 572 out 1027 
subjects underwent both FIT and M2-PK assessment (response rate 55.7%). Subjects with at least one positive fecal test were invited 
to undergo colonoscopy. Among the 93 participants with at least one positive test (positivity rate 16.3%), 13 subjects declined fur-
ther investigations or performed colonoscopy elsewhere due to the waiting time for endoscopic examination, whereas 80 subjects 
underwent colonoscopy (86.0% attendance rate). Of these, 8 subjects reported negative results for neoplasm, 65 subjects were de-
tected with an adenoma that was classified as advanced in 19 cases, and 7 colorectal cancers were diagnosed. 
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the need to avoid including patients with gastroin-
testinal symptoms such as bloating, abdominal 
pain and diarrhea. The study was performed ac-
cording to the Declaration of Helsinki guidelines 
and was approved by the local Ethics Committee. 
All subjects gave their written informed consent 
prior to recruitment.
Methods
Participants were asked to collect two non-watery 
fecal samples for FIT and M2-PK evaluation. A sam-
pling stool device (Eiken Chemical Co., Tokyo, Ja-
pan) and a M2-PK Quick-PrepTM tube (Schebo® Bi-
otech AG, Giessen, Germany) for fecal samples col-
lection were provided with the invitation letter. A 
leaflet reporting a brief description of the screen-
ing procedure and the instruction for stool collec-
tion was included. According to manufacturers’ in-
structions, no dietary or medication restrictions 
were required. Participants were requested to 
maintain fecal samples refrigerated at +4 °C up to 
48 hours until delivery at CPO laboratory. Trained 
technicians performed the fecal tests. All FITs were 
carried out with OC-Sensor-Diana (Eiken Chemical 
Co., Tokyo, Japan) and were considered positive 
for values ≥ 100 ngHb/mL. According to the Faecal 
Immunochemical TesTs for Haemoglobin Evalua-
tion Reporting (FITTER) guidelines (11), OC-SENSOR 
hemoglobin (Hb) concentrations units were con-
verted to micrograms of Hb per gram of feces 
(µgHb/g) multiplying obtained data by a conver-
sion factor of 0.2 (100 ngHb/mL is equal to 20 
µgHb/g feces) (12). Measurement of fecal M2-PK 
was performed in duplicate by using a commer-
cially available kit (Tumor M2-PK™ ELISA Stool Test, 
Schebo® Biotech AG, Giessen, Germany) with a lin-
ear dynamic range of 1-20 units/mL (U/mL) and in-
tra/inter-assay mean coefficient of variance, re-
ported by manufacturer, of 5.3% (range: 3.0-7.9%) 
and 6.8% (range: 4.4-9.4%), respectively. According 
to manufacturer instructions, the positive cut-off 
value was set to 4 U/mL. 
Subjects with at least one positive fecal test were 
invited to undergo colonoscopy. Although un-
common, colonoscopy may lead to complications 
such as perforations, tears or bleeding. For this 
reason, subjects attending colonoscopy were in-
structed on early signs of possible complications 
including abdominal pain, fever or rectal bleeding. 
Endoscopic examination was performed within 2 
months of FIT and M2-PK assessment. Standard 
oral bowel preparation with a 4-L polyethylene 
glycol-electrolyte solution was adopted for colon 
cleansing (4). Colonoscopy was performed by ex-
perienced gastroenterologists of the endoscopy 
unit of Molinette Hospital. Polyps detected during 
each procedure were removed and examined by 
an expert gastrointestinal pathologist who re-
mained blinded to the results of the fecal tests. 
Histology of polyps and cancers was classified ac-
cording to the World Health Organization criteria 
(13). The definition of advanced adenoma includ-
ed all adenomas with a diameter ≥ 10 mm and/or 
villous component ≥ 20% and/or high-grade dys-
plasia, whereas non-advanced adenoma included 
< 10 mm tubular type polyps and low grade dys-
plasia. Cancer was defined as carcinoma invading 
at least the submucosa across the muscolaris mu-
cosa (14).  
Statistical analysis
Normality of data distribution was checked by 
D’Agostino-Pearson test. Age was expressed as 
median and range. FIT and M2-PK concentrations 
were expressed as median and interquartile range. 
Kruskal-Wallis test was used to evaluate differenc-
es in FIT and M2-PK concentrations among sub-
groups, while Fisher’s exact test was employed to 
analyze dichotomous data. The degree of associa-
tion between two continuous variables was ana-
lyzed by Pearson correlation coefficient (r). Positiv-
ity rate was defined as the percentage of positive 
tests among the tested subjects. Adenoma (ADR), 
advanced adenoma (AADR), neoplasm (NDR), ad-
vanced neoplasm (ANDR) and cancer detection 
rate (CDR) for FIT and M2-PK, alone or in combina-
tion, were calculated as the proportion of histo-
logically-proven diagnosis per 100 screened sub-
jects. Positive predictive values (PPVs) were calcu-
lated as the number of histologically-proven diag-
nosis among subjects that underwent colonosco-
py. Number needed to scope (NNS) was defined as 
the number of colonoscopies needed to detect 
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one advanced neoplasm. A P-value < 0.05 was 
considered statistically significant. All statistical 
analyses were performed using MedCalc version 
9.2.1.0. (MedCalc Software bvba, Ostend, Belgium).
Results
Overall, 572 out of 1027 subjects underwent both 
FIT and M2-PK evaluation (response rate 55.7%). At 
least one test was positive in 93 out of 572 sub-
jects (positivity rate 16.3%). FIT was positive in 70 
subject (positivity rate 12.3%; 56 [41-100] µgHb/g) 
and M2-PK in 33 (positivity rate 5.8%; 8 [5-11] U/
mL), whereas both tests were positive in only 10 
participants (positivity rate 1.7%; FIT: 113 [36-240] 
µgHb/g; M2-PK: 11 [5-20] U/mL). The median FIT 
and M2-PK concentration in the total positive co-
hort was 37 (21-116) µgHb/g and 1 (1-5) U/mL, re-
spectively. No correlation was found between the 
two tests in the cohort of 93 subjects (r = -0.07, 
95% confidence interval (CI) = -0.27-0.14; P = 0.501). 
Among the 93 participants with at least one posi-
tive test, 80 subjects underwent colonoscopy 
(86.0% attendance rate). Detection rates, PPVs, 
NNS values and correspondent statistical signifi-
cances are reported in Table 1. Of note is the fact 
that 18 subjects with M2-PK-positivity-only and 
with neoplasm revealed at colonoscopy, repeated 
FIT within one month from the first test before co-
lonoscopy, and 8 out of 18 resulted positive in the 
second round. 
Fecal concentration of FIT and M2-PK in the differ-
ent diagnostic subgroups is shown in Figure 2. Re-
garding FIT concentrations, a statistically signifi-
cant difference was found between subjects with 
adenoma (38 [29-45] µgHb/g) and those with can-
cer (240 [134-240] µgHb/g) (P = 0.023). Conversely, 
M2-PK concentration was significantly different 
between participants with normal colonoscopy 
findings (1 [1-1] U/mL) and subjects with both ade-
noma (1 [1-7] U/mL) and cancer (2 [1-4] U/mL) (P = 
0.037 and P = 0.018, respectively). In addition, no 
Indices FIT M2-PK FIT and M2-PK P* P† P‡
Positive rate 70/572 (12.3%) 33/572 (5.8%) 93/572 (16.3%) < 0.001 0.063 < 0.001
ADR 48/572 (8.4%) 24/572 (4.2%) 65/572 (11.4%) 0.005 0.113 <0.001
AADR 13/572 (2.3%) 10/572 (1.7%) 19/572 (3.3%) 0.675 0.370 0.131
CDR 6/572 (1.0%) 3/572 (0.5%) 7/572 (1.2%) 0.506 1.000 0.342
NDR 54/572 (9.4%) 27/572 (4.7%) 72/572 (12.6%) 0.003 0.108 < 0.001
ANDR 19/572 (3.3%) 13/572 (3.3%) 26/572 (4.5%) 0.370 0.362 0.049




(0.035-0.180) 0.860 0.918 0.986




(0.704-1.133) 0.100 0.198 0.604




(0.212-0.476) 0.150 0.857 0.169
Cancer NNS 10 9 11 0.847 0.961 0.715
Advanced neoplasm NNS 3 2 3 0.381 0.402 0.998
P*: FIT vs. M2-PK
P†: FIT vs. FIT and M2-PK combination
P‡: M2-PK vs. FIT and M2-PK combination
All statistical analyses were performed by Fisher’s exact test.
AADR - advanced adenoma detection rate; ADR - adenoma detection rate; ANDR - advanced neoplasm detection rate; CDR - cancer 
detection rate; CI - confidence interval; FIT - fecal immunochemical test for hemoglobin; M2-PK - M2-type pyruvate kinase; NDR - 
neoplasm detection rate; NNS - number needed to scope; PPV - positive predictive value.
Table 1. Screening indices of FIT and M2-PK, alone or in combination.
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differences were found in the concentration of 
both FIT and M2-PK between non-advanced and 
advanced adenomas (34 [20-70] µgHb/g vs. 32 [13-
219] µgHb/g, P = 0.679, and 1 [1-8] U/mL vs. 4 [1-7] 
U/mL, P = 0.077, respectively. All subjects with 
negative results had M2-PK levels below the assay 
detection limit (< 1.00 U/mL).  
Discussion
To our knowledge, this is the first study investigat-
ing fecal M2-PK assessment either in comparison 
or in combination to FIT in a real practice first-
round CRC screening program. Overall positivity 
rate increased from 12.3% to 16.3% with the addi-
tion of M2-PK test to FIT (P = 0.063). In particular, 
fecal M2-PK assessment permitted the detection 
of 18 FIT-negative subjects with neoplasm re-
vealed at colonoscopy. In 2006, Shastri and col-
leagues compared fecal M2-PK to guaiac-based fe-
cal occult blood test in a total of 317 consecutive 
subjects with various clinical diagnoses. They re-
ported a lower specificity for M2-PK that led to an 
unacceptable high number of false positive results 
and in turn reduces colonoscopy appropriateness 
(15). Subsequently, the authors compared M2-PK 
with FIT in a cohort made of 640 symptomatic 
subjects and found that FIT had a significantly 
higher specificity, PPV, and positive likelihood ra-
tios compared to M2-PK (16). More recently, in a 
prospective multicenter Italian study, it has been 
reported that FIT in combination with fecal M2-PK 
assessment had a high sensitivity (91%) and nega-
tive predictive value (97%) for CRC detection en-
couraging their use in clinical practice for a more 
appropriate management of colonoscopy waiting 
lists (17). In addition, Kim and colleagues, in a case-
control study, found that immuno-chromato-
graphic M2-PK test was superior to FIT in terms of 
sensitivity for both CRC and adenomas detection 
(92.8% vs. 47.5% and 69.4% vs. 12.1%, respectively) 
(18). However, previous studies were performed 
on symptomatic patients recruited in clinical set-
tings. Leen and colleagues performed the first 
study to assess the performance of fecal M2-PK 
addition to FIT-based screening program (10). The 
authors reported a significant improvement in 
ADR leading to the identification and removal of 
70% more polyps. However, the study was per-
formed within a second round of a screening pro-

































P = 0.066 P = 0.084
P = 0.018
P = 0.037
Figure 2. FIT (A) and M2-PK (B) concentrations in the different subgroups of subjects according to colonoscopy findings. 
All statistical analyses were performed by Kruskal-Wallis test. P values in top right corner refer to FIT (A) and M2-PK (B) median com-
parison between all three subgroups simultaneously. 
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tive conclusions about the potential role of the 
combined approach in a first-round screening.  
In the present study, from a total of 1027 subjects 
invited, 572 (55.7%) accepted to participate and 
provided samples for both FIT and M2-PK. Accord-
ing to the Italian Group for Colorectal Cancer 
Screening (GISCoR) “Operative report of quality in-
dicators”, participation rate was more than accept-
able (acceptable > 45%, desirable > 65%) (19), indi-
cating that the addition of fecal M2-PK assessment 
to the screening protocol did not significantly re-
duce compliance and, subsequently, screening 
program performance. Positivity rate was signifi-
cantly lower for fecal M2-PK compared to FIT (5.8% 
vs. 12.3%, P < 0.001) denoting a higher specificity 
for M2-PK test. However, no differences were 
found regarding PPVs between the two tests (can-
cer PPV, P = 0.860; neoplasm PPV, P = 0.100; and 
advanced neoplasm PPV, P = 0.150). Interestingly, 
only 10 subjects had both FIT and M2-PK positive. 
In fact, FIT-positivity is related to bleeding adeno-
mas and tumors whereas M2-PK-positivity is relat-
ed to the release in feces of a metabolic biomarker 
characteristic of tumor cells and their precursors 
(6). The discrepancy among the results may be ex-
plained by the different parameters analyzed by 
these two tests. However, the observed variance 
supports the usefulness of a combined screening 
approach based on both FIT and fecal M2-PK eval-
uation. In fact, the addition of fecal M2-PK led to 
the identification of 18 neoplasms that resulted 
negative to FIT. Importantly, the eventual use of 
the combined approach will not significantly im-
prove colonoscopy workload, as deduced by the 
comparable cancer and advanced neoplasm NNS 
(P = 0.961 and P = 0.402, respectively).
Regarding fecal M2-PK levels, we did not find any 
significant difference between cancers and adeno-
mas (P = 0.630). Conversely, Koss and colleagues 
previously reported a significant increase in M2-PK 
concentrations in adenoma-carcinoma sequence 
progression (20). This discrepancy could be ex-
plained by both the low number of CRCs found in 
our study which may have reduced the statistical 
power of the analysis, and the different population 
studied. 
One limitation of our study is the absence of endo-
scopic investigation in all participants, which did 
not allow to calculate the sensitivity and specificity 
of FIT and fecal M2-PK for neoplasm detection. 
However, this research was carried out under real 
practice condition, and consequently, colonosco-
pies were not performed in subjects with negative 
fecal tests results.
In conclusion, fecal M2-PK is not a reliable alterna-
tive to FIT for CRC screening but when combined 
with FIT offers the potential to detect additional 
adenomas and cancers that either do not bleed or 
only bleed intermittently without reducing partici-
pation rate and without increasing endoscopy 
workload. Further studies taking into account al-
ternative cut-off values and/or different strategies 
for priority management of endoscopic examina-
tion are necessary. Moreover, a cost-benefit analy-
sis is still required to evaluate the affordability of 
FIT and fecal M2-PK combined approach in the 
setting of CRC screening programs. 
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